What Is Ferroptosis? The Iron-Driven Cell Death Explained Simply

Written by the Nuvirox Research Team

Short answer: ferroptosis is a form of programmed cell death in which iron drives the oxidation of polyunsaturated fats in a cell's membranes until the membrane fails. It is held back mainly by the enzyme GPX4 (powered by glutathione) and a parallel coenzyme Q10 system. With honest caveats: almost everything known comes from cells and animals, and nothing shows a supplement can switch it on or off in healthy people.

What is ferroptosis, in plain terms?

Ferroptosis is cell death by membrane rusting. Iron catalyzes chain reactions that oxidize the fats in cell membranes, and if the cell's repair systems can't keep up, the membrane loses integrity and the cell dies.

The term was coined by Scott Dixon, Brent Stockwell and colleagues in a 2012 paper in Cell. They were studying erastin, an experimental compound that killed certain cancer cells in an unusual way. The death depended on iron inside the cell but not on other metals, and it looked nothing like apoptosis, necrosis or autophagy. They named it from the Latin ferrum (iron) and the Greek ptosis (falling) [1]. Erastin worked by cutting off cystine, which cells need to make glutathione.

The vulnerability comes from the membranes themselves. Polyunsaturated fatty acids (PUFAs), the fats with several double bonds, keep membranes flexible, but those double bonds are easy targets for oxidation. A 2017 consensus review described ferroptosis as "an ancient vulnerability" caused by building PUFAs into cell membranes. Cells evolved elaborate defenses against it [5].

How is ferroptosis different from apoptosis?

Apoptosis is a tidy, enzyme-driven self-dismantling. Ferroptosis is an oxidative failure of the membrane. They use different machinery and respond to different blockers.

In apoptosis, enzymes called caspases cut the cell apart from the inside, and it is packaged for clean removal. Ferroptosis doesn't need caspases. Drugs that block apoptosis don't stop it, while iron chelators and lipid-soluble antioxidants do.

What stops ferroptosis from happening in healthy cells?

Two main brakes. One is the enzyme GPX4, which uses glutathione to convert lipid peroxides into harmless alcohols. The other is the FSP1–coenzyme Q10 system, which traps the radicals that spread the chain reaction.

GPX4 and glutathione. In 2014, Wan Seok Yang and colleagues tested 12 different ferroptosis-inducing compounds. They found that every one ultimately disabled glutathione peroxidase 4 (GPX4). Some did it by depleting glutathione and others by inhibiting the enzyme directly [2]. Raising or lowering GPX4 changed how lethal all 12 compounds were, but it didn't change the lethality of 11 compounds that kill by other routes. GPX4 is the main guardian. It is also why glutathione sits at the center of this story. For a broader look at that molecule, see our explainer on glutathione and fatigue.

FSP1 and coenzyme Q10. Two papers published together in Nature in 2019 found a second, independent brake. A protein previously called AIFM2, renamed ferroptosis suppressor protein 1 (FSP1), regenerates the reduced form of coenzyme Q10 (ubiquinol) outside the mitochondria. Ubiquinol then acts as a radical-trapping antioxidant within the membrane [3][4]. FSP1 levels tracked with ferroptosis resistance across hundreds of cancer cell lines [4].

Where does NADPH fit in?

NADPH is the fuel behind both brakes. It regenerates glutathione for GPX4, and FSP1 uses NAD(P)H to recycle coenzyme Q10. A cell low on NADPH runs short on defenses.

Glutathione is used up as GPX4 works and has to be recycled back to its reduced form, and that recycling consumes NADPH. The 2019 FSP1 paper explicitly described an "FSP1–CoQ10–NAD(P)H pathway" [3]. In a 2016 analysis of the NCI-60 cancer cell line panel, Stockwell's group found that NADPH abundance predicted how sensitive a cell line was to ferroptosis-inducing compounds, and they validated this experimentally [6]. If you're new to the molecule, our guide to what NADPH is covers the basics. In most cells, a major source of NADPH is the pentose phosphate pathway, a side branch of glucose metabolism. NADP⁺ is itself made from NAD⁺, an indirect link that hasn't been tested as an intervention in people.

Do mitochondria play a role?

Yes, but it's a supporting role, and it depends on the context. Mitochondria produce reactive oxygen species and handle much of the cell's iron, so they can feed the lipid peroxidation that drives ferroptosis. But the main defenses work largely outside them.

The ferroptotic cells in the original 2012 work had visibly shrunken mitochondria with condensed membranes [1]. The 2022 review "Ferroptosis turns 10" frames it within metabolism, reactive oxygen and iron biology together, not as a purely mitochondrial event [7]. The electrical charge across the inner mitochondrial membrane affects how much reactive oxygen these organelles produce. Our explainer on mitochondrial membrane potential covers why that charge matters for both energy output and oxidative stress.

What the research actually shows

The mechanism is well established in cells and animals. Evidence in humans is thin, and the one large clinical test of an iron-targeting strategy was negative.

Dixon et al., 2012 (cell and tissue models). In cancer cell lines and rat brain slices, erastin-triggered death depended on iron and was blocked by an experimental inhibitor, ferrostatin-1. Glutamate-induced death in the brain slices was also blocked, which hinted at a link to neuronal injury [1].

Yang et al., 2014 (cell lines plus mouse models). GPX4 was the common target of 12 ferroptosis inducers. In a screen of 177 cancer cell lines, certain lymphoma and kidney cancer lines were particularly sensitive [2].

Why that trial matters here. Iron buildup and ferroptosis are leading hypotheses in neurodegeneration research. The 2017 consensus review lists Parkinson's, Alzheimer's and Huntington's diseases among conditions where ferroptosis has been implicated [5]. FAIRPARK-II was a large, well-run test of a related idea, lowering iron, and it went the wrong way [8]. It didn't test ferroptosis directly, but it shows the jump from a clean cell-culture mechanism to human benefit is not automatic.

What this doesn't mean

It doesn't mean ferroptosis is something you can feel, test for at home or "prevent" with a supplement. There's no clinical test for ferroptosis in a living person.

• It's not just "bad." Ferroptosis may also act as a natural defense, removing damaged or potentially cancerous cells. The 2017 review notes a possible tumor-suppressing role [5]. Blocking it everywhere would not obviously be good.
• More antioxidants aren't automatically better. The defenses are specific: GPX4, glutathione recycling and membrane-located CoQ10. Generic antioxidant intake has not been shown to change ferroptosis in human tissue.
• Iron isn't the enemy. You need iron for oxygen transport and energy production. Both too much and too little cause problems, which is why iron changes belong with a blood test and a clinician, not a theory about cell death.

If you've come here because of a diagnosis, such as a neurological condition, kidney injury or iron disorder, the ferroptosis literature is interesting background but no basis for self-directed changes. Talk to your doctor before changing iron intake or starting high-dose antioxidants.

What actually influences the brakes?

Everyday factors that plausibly affect these defenses are the ones that support overall redox balance. They include adequate protein (cysteine is the limiting building block for glutathione), normal iron status and metabolic health. None has been tested against ferroptosis outcomes in people.

Research reviews tie ferroptosis sensitivity to amino acid, iron and PUFA metabolism, and to the production of glutathione, NADPH and coenzyme Q10 [5]. That points to familiar basics: enough protein, no iron supplements without a blood test showing a need, and regular activity. Our overview of oxidative stress explains why the body's own defense systems matter more than single antioxidant pills. NAD⁺ precursors sit upstream of NADP⁺ and NADPH. That makes them a reasonable research question, not a demonstrated anti-ferroptosis strategy.

Frequently asked questions

Is ferroptosis the same as oxidative stress?
No. Oxidative stress is a broad imbalance between oxidants and antioxidant defenses. Ferroptosis is a specific cell-death program in which iron-driven oxidation of membrane fats becomes lethal.

Can you prevent ferroptosis with supplements?
There's no human evidence for that. No trial has shown that a supplement measurably changes ferroptosis in people.

Does ferroptosis have anything to do with aging?
Researchers think it may. Reviews list aging among the contexts where ferroptosis has been implicated, alongside development and immunity [7]. The evidence is mostly from animals and cells, and whether it's a driver of human aging or a side effect of it is still open.

What is GPX4, in simple terms?
GPX4 is an enzyme that repairs oxidized fats in cell membranes before they set off a chain reaction. It uses glutathione as its helper, and selenium is built into its active site. When GPX4 is inhibited in cells, they undergo ferroptosis [2].

Is CoQ10 related to ferroptosis?
Yes, mechanistically. The FSP1 system recycles coenzyme Q10 into its reduced form, which traps lipid radicals in membranes [3][4]. That finding comes from cell and mouse work, though. It doesn't show that oral CoQ10 changes ferroptosis in people.

The bottom line

Ferroptosis is iron-driven cell death caused by runaway oxidation of membrane fats. GPX4 and glutathione hold it back, FSP1 and coenzyme Q10 back them up, and NADPH supplies the reducing power behind both.

The fair reading is that this is a strong mechanism with weak human data. Treat any product or protocol that claims to "stop ferroptosis" with skepticism.

References

1. Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149(5):1060-1072. DOI: 10.1016/j.cell.2012.03.042. PMID: 22632970. PMCID: PMC3367386.
2. Yang WS, SriRamaratnam R, Welsch ME, et al. Regulation of ferroptotic cancer cell death by GPX4. Cell. 2014;156(1-2):317-331. DOI: 10.1016/j.cell.2013.12.010. PMID: 24439385. PMCID: PMC4076414.
3. Doll S, Freitas FP, Shah R, et al. FSP1 is a glutathione-independent ferroptosis suppressor. Nature. 2019;575(7784):693-698. DOI: 10.1038/s41586-019-1707-0. PMID: 31634899.
4. Bersuker K, Hendricks JM, Li Z, et al. The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. Nature. 2019;575(7784):688-692. DOI: 10.1038/s41586-019-1705-2. PMID: 31634900. PMCID: PMC6883167.
5. Stockwell BR, Friedmann Angeli JP, Bayir H, et al. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell. 2017;171(2):273-285. DOI: 10.1016/j.cell.2017.09.021. PMID: 28985560. PMCID: PMC5685180.
6. Shimada K, Hayano M, Pagano NC, Stockwell BR. Cell-line selectivity improves the predictive power of pharmacogenomic analyses and helps identify NADPH as biomarker for ferroptosis sensitivity. Cell Chem Biol. 2016;23(2):225-235. DOI: 10.1016/j.chembiol.2015.11.016. PMID: 26853626. PMCID: PMC4792701.
7. Stockwell BR. Ferroptosis turns 10: emerging mechanisms, physiological functions, and therapeutic applications. Cell. 2022;185(14):2401-2421. DOI: 10.1016/j.cell.2022.06.003. PMID: 35803244. PMCID: PMC9273022.
8. Devos D, Labreuche J, Rascol O, et al. Trial of deferiprone in Parkinson's disease. N Engl J Med. 2022;387(22):2045-2055. DOI: 10.1056/NEJMoa2209254. PMID: 36449420.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical advice.